KR100215616B1 - 3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물 - Google Patents

3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물 Download PDF

Info

Publication number
KR100215616B1
KR100215616B1 KR1019910008144A KR910008144A KR100215616B1 KR 100215616 B1 KR100215616 B1 KR 100215616B1 KR 1019910008144 A KR1019910008144 A KR 1019910008144A KR 910008144 A KR910008144 A KR 910008144A KR 100215616 B1 KR100215616 B1 KR 100215616B1
Authority
KR
South Korea
Prior art keywords
compound
piperazinyl
methyl
indazol
butyl
Prior art date
Application number
KR1019910008144A
Other languages
English (en)
Other versions
KR910020007A (ko
Inventor
니콜라스제이.리브
죠샙티.스트러프체프스키
존지.저캑
케니쓰보듀
Original Assignee
제이 티. 쉑 2세
훽스트-러셀 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이 티. 쉑 2세, 훽스트-러셀 파마슈티칼즈 인코포레이티드 filed Critical 제이 티. 쉑 2세
Publication of KR910020007A publication Critical patent/KR910020007A/ko
Application granted granted Critical
Publication of KR100215616B1 publication Critical patent/KR100215616B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 3-[1-티아졸리디닐부틸-4-피페라지닐]-1H-인다졸 및 약제학적으로 허용되는 이의 산 부가염, 경우에 따라, 이의 광학적, 기하학적 및 입체 이성체, 및 이의 라세미 혼합물에 관한 것이다.
상기식에서,
R1및 R2는 각각 수소 또는 저급 알킬이거나, 또는 이들이 결합된 탄소원자와 함께 사이클로펜탄, 사이클로헥산 또는 사이클로 헵탄 환을 형성하고, R3및 R4는 각각 수소 또는 저급 알칼이거나, 또는 이들이 결합된 탄소원자와 함께 사이클로펜탄, 사이클로헥산 또는 사이클로 헵탄 환을 형성하며, R5는 수소, 저급 알킬, 알카노일 또는 아로일이고, x는 할로겐, 저급 알킬 또는 알콕시이며, m은 0 내지 3 의 정수이다.
본 발명의 화합물은 정신병 치료제로서 유용하다.

Description

3-[1-티아졸리디닐부틸-4-피페라지닐]-1H-인다졸, 이의 제조방법 및 이를 함유하는 약제학적 조성물
본 발명은 하기 일반식(Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 산 부가염 및 경우에 따라, 이의 광학 및 기하 입체 이성체 및 이들의 라세미 혼합물에 관한 것이다;
1 2 3 4 5 1 2 5
1 2 3 4 3 5 5 3 1 2 3 4 1 2 6 3 4 6 6 3 4 6
50 2 2 2 2 4 7 12 2 2 4 8 14 2 4 10 18 2 3 2 2 4 21 31 5 2 4 2 3 2 2 4 23 33 5 2 19 27 5 2 4 11 18 2 3 2 2 4 22 31 5 2 3 2 2 4 23 33 5 2 2 11 13 4 2 4 23 32 5 2 2 4 22 30 5 2 2 4 19 26 5 2 3 2 2 4 20 28 5 2 4 2 4 11 14 4 2 4 20 29 5 2 2 2 4 21 31 5

Claims (10)

  1. (2회 정정) 하기 일반식(Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 산 부가염, 이의 광학 및 기하 입체 이성체 및 이의 라세미 혼합물.
    상기식에서,
    R1및 R2는 각각 독립적으로 수소 또는 메틸이거나, 이들이 결합되어 있는 탄소원자와 함께 사이클로펜탄 환 또는 사이클로헥산 환을 형성하고,
    R3및 R4는 각각 독립적으로 수소 또는 메틸이거나, 이들이 결합되어 있는 탄소원자와 함께 사이클로펜탄 환 또는 사이클로헥산 환을 형성하며,
    R5는 수소이고
    X는 할로겐 또는 메틸이며,
    m은 0 또는 1 의 정수이다.
  2. (2회 정정) 제 1 항에 있어서, R3및 R4가 각각 독립적으로 수소 또는 메틸이고, R5가 수소이며, X가 할로겐이고 m이 0 또는 1 인 화합물.
  3. 제 2 항에 있어서, R3및 R4가 각각 독립적으로 수소 또는 메틸이고, R5가 수소이며, X가 불소이고, m이 0 또는 1 인 화합물.
  4. 제 1 항에 있어서, 2-(4-(1-[1H-인다졸-3-일]-4-피페라지닐)부틸)-1-티아-3-아자스피로[4,5]데칸-4-온인 화합물.
  5. 제 1 항에 있어서, 3-(4-[1-(6-플루오르-1H-인다졸-3-일)-4-피페라지닐]부틸)-5-메틸-4-티아졸리디논인 화합물.
  6. 제 1 항에 있어서 3-(4-[1-(6-플루오르-1H-인다졸-3-일)-4-피페라지닐]부틸)-1-티아-3-아자스피로[4,5]데칸-4-온인 화합물.
  7. 제 1 항에 있어서, 3-(4-(1-[1H-인다졸-3-일]-4-피페라지닐)부틸)-1-티아-3-아자스피로[4,4]노난-4-온인 화합물.
  8. 제 1 항에 있어서, 3-(4-(1-[1H-인다졸-3-일]-4-피페라지닐)부틸)-5,5-디메틸-4-티아졸리디논인 화합물.
  9. 활성 성분으로서의 제 1 항의 화합물과 약제학적으로 허용되는 이의 담체를 포함하는, 정신병 치료용 약제학적 조성물.
  10. (2회 정정) 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시킴을 포함하여 제 1 항에 따른 하기 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서,
    R1, R2, R3, R4, R3, X 및 m은 제 1 항에서 정의한 바와 같다.
KR1019910008144A 1990-05-21 1991-05-20 3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물 KR100215616B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/526,089 US5041445A (en) 1990-05-21 1990-05-21 3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles
US526,089 1990-05-21

Publications (2)

Publication Number Publication Date
KR910020007A KR910020007A (ko) 1991-12-19
KR100215616B1 true KR100215616B1 (ko) 1999-08-16

Family

ID=24095872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008144A KR100215616B1 (ko) 1990-05-21 1991-05-20 3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물

Country Status (23)

Country Link
US (1) US5041445A (ko)
EP (1) EP0458234B1 (ko)
JP (1) JP3161755B2 (ko)
KR (1) KR100215616B1 (ko)
AT (1) ATE178327T1 (ko)
AU (1) AU642243B2 (ko)
CA (1) CA2042982A1 (ko)
CZ (1) CZ280005B6 (ko)
DE (1) DE69131057T2 (ko)
DK (1) DK0458234T3 (ko)
ES (1) ES2130125T3 (ko)
FI (1) FI94757C (ko)
GR (1) GR3030233T3 (ko)
HU (1) HU215845B (ko)
IE (1) IE911708A1 (ko)
IL (1) IL98184A (ko)
MX (1) MX25858A (ko)
NO (1) NO179749C (ko)
NZ (1) NZ238184A (ko)
PL (1) PL165731B1 (ko)
PT (1) PT97720B (ko)
RU (2) RU2038355C1 (ko)
ZA (1) ZA913794B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3875073T2 (de) * 1987-11-20 1993-03-11 Hoechst Roussel Pharma 3-(4(1-substituierte-4-piperazinyl)butyl)-4-thiazolidinone, verfahren zu deren herstellung und ihre anwendung als arzneimittel.
US5801186A (en) 1987-11-20 1998-09-01 Hoechst Marion Roussel, Inc. 3- 4-(1-substituted-4-piperazinyl)butyl!-4-thiazolidinone and related compounds
CA2157348A1 (en) * 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
KR20100053626A (ko) * 2007-08-15 2010-05-20 메모리 파마슈티칼스 코포레이션 5-ht6 수용체 친화성을 나타내는 3'-치환된 화합물
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
JP5760300B2 (ja) 2009-09-10 2015-08-05 株式会社リコー インクジェット用インク組成物材料及びインクジェット用インク組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100282A (en) * 1972-12-23 1978-07-11 Boehringer Ingelheim Gmbh N-Aryl-N'-(phenyl- or phenoxy-alkyl)-piperazines and salts thereof
DE3132916A1 (de) * 1981-08-20 1983-03-03 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenylindazol-3-on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4775761A (en) * 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
DE3875073T2 (de) * 1987-11-20 1993-03-11 Hoechst Roussel Pharma 3-(4(1-substituierte-4-piperazinyl)butyl)-4-thiazolidinone, verfahren zu deren herstellung und ihre anwendung als arzneimittel.
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
GR3030233T3 (en) 1999-08-31
EP0458234B1 (en) 1999-03-31
HU215845B (hu) 1999-04-28
FI912401A (fi) 1991-11-22
FI94757C (fi) 1995-10-25
HU911697D0 (en) 1991-11-28
PT97720A (pt) 1992-02-28
US5041445A (en) 1991-08-20
KR910020007A (ko) 1991-12-19
JP3161755B2 (ja) 2001-04-25
RU2038355C1 (ru) 1995-06-27
FI912401A0 (fi) 1991-05-17
NZ238184A (en) 1993-01-27
PL165731B1 (pl) 1995-02-28
IE911708A1 (en) 1991-12-04
MX25858A (es) 1993-09-01
CZ148091A3 (en) 1993-08-11
DE69131057D1 (de) 1999-05-06
NO179749B (no) 1996-09-02
NO179749C (no) 1996-12-11
IL98184A (en) 1995-03-15
JPH04226979A (ja) 1992-08-17
EP0458234A3 (en) 1992-09-30
DK0458234T3 (da) 1999-10-11
ES2130125T3 (es) 1999-07-01
NO911921D0 (no) 1991-05-16
HUT61018A (en) 1992-11-30
IL98184A0 (en) 1992-06-21
EP0458234A2 (en) 1991-11-27
AU7618191A (en) 1991-11-21
CZ280005B6 (cs) 1995-09-13
FI94757B (fi) 1995-07-14
RU2105765C1 (ru) 1998-02-27
DE69131057T2 (de) 1999-09-09
CA2042982A1 (en) 1991-11-22
ATE178327T1 (de) 1999-04-15
NO911921L (no) 1991-11-22
AU642243B2 (en) 1993-10-14
ZA913794B (en) 1992-02-26
PT97720B (pt) 1998-09-30
PL290327A1 (en) 1992-05-04

Similar Documents

Publication Publication Date Title
KR100215616B1 (ko) 3-(1-티아졸리디닐부틸-4-피페라지닐)-1h-인다졸,이의 제조방법및 이를함유하는약제학적조성물
ES2170080T3 (es) Derivados de 2-(1-(1,3-tiazolin-2-il)azetidin-3-il)tio-carbapenem.
ES537182A0 (es) Procedimiento de obtencion de compuestos de 1-aril-2-(3-(4-trifluormetilestiril)-1,2,4-triazol-1-il)-1-c 1,2,4,-triazol-1-il-metil) etanol de efecto antifugal.
HUT40668A (en) Process for preparing new benzoxazole and amine derivatives and pharmaceutical compositions containing such compounds
HUT68721A (en) Benzofuran and benzizoxazole derivatives, pharmaceutical composition containing said compounds as active agent and process for preparing them
PT74912B (en) Process for preparing anti-hypertensive 1-substituted siro <piperidine-oxobenzoxazine>s
IL106307A (en) Isoxazole derivatives for the treatment of irritable bowel syndrome
HUT65268A (en) Process for preparation of optically active 2-amino-1,2,3,4-tetrahydro-naphtaline derivatives
KR920016452A (ko) N-(아릴옥시알킬)헤테로아릴-8-아자비시클로[3.2.1]옥탄, 중간체, 이의 제조방법 및 약제로서 이의 용도
ZA994201B (en) Nitron compounds, a process for their preparation and pharmaceutical compositions containing them.
RU93005087A (ru) 3-(тиазолидинилбутил-4-пиперазинил)-ih-индазолы
HUT53592A (en) Process for producing acyloxy-propanolamines and pharmaceutical compositions containing them as active components
GR3023381T3 (en) Process for preparing trans-piperidine-2,5-dicarboxylates
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
FI914224A0 (fi) Typpiheterosyklien substituoidut 2-propenyylijohdannaiset
IL99434A0 (en) 3-(1h-indazol-3-yl)-4-pyridinamines,a process and intermediates for their preparation and pharmaceutical compositions containing them
KR850007061A (ko) 모노실릴화 아미노페닐에틸아민 유도체의 제조방법
NO871140L (no) Fremgangsmaate ved fremstilling av nye 1-(3-(2-(4-morfolinyl)-etoksy)-(2-dialkylaminoetoksy)-2-tienyl)-3-fenyl-propanoner og syreaddisjonssalter derav.
AU646611B2 (en) 4-{4- or 6-(trifluoromethyl-2-pyridinyl)}-1-piperazinyl- alkyl substituted lactams
FI834798A0 (fi) Foerfarande foer framstaellning av 1-(aminoalkoxifenyl)-1-fenyl-propanoler
PT74966B (en) N-<2-(2-amino-2-phenylethyl)phenyl>-2,2-dimethyl-propanamid and derivatives and a process for preparing the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020517

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee